EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Empagliflozin attenuates ventricular fibrillation postmyocardial infarction associated with reduced transforming growth factor- β 1/Smad3 signaling and miR-181a expression

Jingsong Shen, Min Huang, Zixu Ye, Yuling Jing, Ziyang Yuan, Zeming Xiang, Miao Ding, Tao Li, Qiang Ye iD

Journal of International Medical Research · 2025

DOI: 10.1177/03000605251353040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of International Medical Research, 2025. Verfasst von Jingsong Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Affiliated Hospital of Southwest Medical University, China. Hauptthemen laut MEDLINE: MicroRNAs, Glucosides, Transforming Growth Factor beta1, Ventricular Fibrillation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Project of Sichuan Province, Open Fund of Medical Electrophysiological Key Laboratory of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine whether empagliflozin reduces ventricular fibrillation and myocardial fibrosis after myocardial infarction via the transforming growth factor-β1/Smad3/miR-181a pathway.

Methods

Male nondiabetic Sprague–Dawley rats (n = 16) were randomized into sham, myocardial infarction, low-dose empagliflozin (10 mg/kg/day), and high-dose empagliflozin (30 mg/kg/day) groups. Myocardial infarction was induced via coronary artery ligation. After 4 weeks, ventricular fibrillation thresholds were assessed via electrical stimulation. Cardiac function (echocardiography), fibrosis (Masson’s trichrome staining), and molecular markers (transforming growth factor-β1, Smad3, miR-181a; assessed via western blotting/quantitative polymerase chain reaction) were analyzed.

Results

Empagliflozin-treated groups showed reduced left ventricular dilation (left ventricular internal diameters at end-diastole: 8.2 ± 0.3 vs. 9.1 ± 0.4 mm in myocardial infarction; left ventricular internal diameters at end-systole: 5.1 ± 0.2 vs. 6.0 ± 0.3 mm) and improved ejection fraction (45% vs. 38% in myocardial infarction). Ventricular fibrillation thresholds increased significantly with empagliflozin administration (p < 0.05). Myocardial fibrosis (collagen volume fraction: 12% vs. 25% in myocardial infarction) and transforming growth factor-β1/Smad3/miR-181a expression were downregulated in empagliflozin groups (p < 0.01). No dose-dependent differences were observed between the groups.

Conclusions

Empagliflozin attenuates postmyocardial infarction ventricular arrhythmias and fibrosis associated with the suppression of transforming growth factor-β1/Smad3 signaling and miR-181a expression, enhancing cardiac function. These findings highlight its therapeutic potential in postinfarct remodeling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsGlucosidesTransforming Growth Factor beta1Ventricular FibrillationSmad3 ProteinBenzhydryl CompoundsMyocardial InfarctionSodium-Glucose Transporter 2 InhibitorsAnimalsRats, Sprague-DawleySignal TransductionRatsMaleFibrosisMyocardiumDisease Models, AnimalGene Expression Regulation

Stichwörter der Autor:innen

EmpagliflozinmiR-181amyocardial infarctiontransforming growth factor-β1/Smad3 pathwayventricular arrhythmia

Substanzen

MicroRNAsGlucosidesTransforming Growth Factor beta1Smad3 ProteinBenzhydryl CompoundsempagliflozinSmad3 protein, ratMIRN181 microRNA, ratTgfb1 protein, ratSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, The Affiliated Hospital of Southwest Medical University, China.
  • School of Basic Medical Sciences, Southwest Medical University, China.
  • Key Laboratory of Medical Electrophysiology of the Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Collaborative Innovation Center for Prevention and Treatment of Cardiovascula…

ORCID-Profile: Qiang Ye

Förderung

  • Medical Research Project of Sichuan Province
  • Open Fund of Medical Electrophysiological Key Laboratory of Sichuan Province

Zitieren

APA

Shen, J., Huang, M., Ye, Z., Jing, Y., Yuan, Z., Xiang, Z., Ding, M., Li, T., & Ye, Q. (2025). Empagliflozin attenuates ventricular fibrillation postmyocardial infarction associated with reduced transforming growth factor- β 1/Smad3 signaling and miR-181a expression. Journal of International Medical Research. https://doi.org/10.1177/03000605251353040

Vancouver

Shen J, Huang M, Ye Z, Jing Y, Yuan Z, Xiang Z, et al. Empagliflozin attenuates ventricular fibrillation postmyocardial infarction associated with reduced transforming growth factor- β 1/Smad3 signaling and miR-181a expression. Journal of International Medical Research. 2025. doi:10.1177/03000605251353040

BibTeX
@article{Shen2025,
  author = {Shen, Jingsong and Huang, Min and Ye, Zixu and Jing, Yuling and Yuan, Ziyang and Xiang, Zeming and Ding, Miao and Li, Tao and Ye, Qiang},
  title = {Empagliflozin attenuates ventricular fibrillation postmyocardial infarction associated with reduced transforming growth factor- β 1/Smad3 signaling and miR-181a expression},
  journal = {Journal of International Medical Research},
  year = {2025},
  doi = {10.1177/03000605251353040}
}
Kostenlos starten →